Abstract
From the data analysis perspective, clinical statisticians are typically faced with continuous data, discrete data, or time-to-event data. For early Phase II clinical trials, the most frequently seen data types are continuous data or binary data. In this chapter, and the next two chapters covering data analysis, the discussion will mainly be about analyzing continuous data or binary data.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chuang-Stein, C., Kirby, S., French, J., Kowalski, K., Marshall, S., Smith, M. K., et al. (2011). A Quantitative approach for making Go/NoGo decisions in drug development. Drug Information Journal, 45(2), 187–202.
Mallinckrodt, C. H., Lane, P. W., Schnell, D., Peng, Y., & Mancuso, J. P. (2008). Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal, 42, 303–319.
SAS User’s Manual, SAS Inc—SAS™ System (SAS Institute Inc., Cary, North Carolina), version 9.4.
Ting, N. (2000). Carry-forward analysis, encyclopedia of biopharmaceutical statistics (pp. 103–109). New York: Marcel Dekker, Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ting, N., Chen, DG., Ho, S., Cappelleri, J.C. (2017). Analysis of a Proof of Concept Study. In: Phase II Clinical Development of New Drugs. ICSA Book Series in Statistics. Springer, Singapore. https://doi.org/10.1007/978-981-10-4194-5_8
Download citation
DOI: https://doi.org/10.1007/978-981-10-4194-5_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-4192-1
Online ISBN: 978-981-10-4194-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)